Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibalizumab and Chidamide in People Living With HIV
NCT07635992Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2026
- Primary completion
- Dec 2028
01
Overview
Phase 1, open-label, single-arm trial of ibalizumab and tucidinostat in human immunodeficiency virus infection (HIV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Treatment-Emergent Adverse Events at 24 weeks and Discontinuation or Interruption due to Adverse Events at 24 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ibalizumabtucidinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07635992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635992.